Melanin-dependent pyroptosis induces selective tumor killing and durable antitumor immune response in melanoma
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Inflammasome and immune disorders · interferon and immune responses · Ferroptosis and cancer prognosis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (47)
Show source-provided references
1. Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance10.1038/s41568-024-00723-5 ↗
2. Engineering CAR-T therapeutics for enhanced solid tumor targeting
3. Advances in antibody-based therapy in oncology10.1038/s43018-023-00516-z ↗
4. Engineered antibodies that stabilize drug-modified KRASG12C neoantigens enable selective and potent cross-HLA immunotherapy10.1038/s41467-025-66132-w ↗
5. Landscape of subcutaneous administration strategies for monoclonal antibodies in oncology10.1002/adma.202406604 ↗
6. FDA approves 100th small-molecule kinase inhibitor10.1038/d41573-025-00188-7 ↗
7. NIR emissive functional nanoparticles promote precise pancreatic cancer therapy by co-targeting mutant p53 and oncogenic KRAS10.1002/adfm.202312610 ↗
8. Brain-targeted codelivery of Bcl-2/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy10.1021/acsnano.2c00320 ↗
9. Synthetically Lethal Biomimetic Nutri-hijacker Hitchhikes and Reprograms KRAS Mutation-Driven Metabolic Addictions for Pancreatic Ductal Adenocarcinoma Treatment10.1021/acsnano.3c04069 ↗
10. Tumour-agnostic kinase inhibitors10.1038/s41573-025-01147-y ↗
11. Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors10.1038/s41591-024-03244-8 ↗
12. A bio-inspired free-standing film with versatility: from heterogeneous CTCs programed isolating to breast cancer molecular typing10.1002/adma.202309046 ↗
13. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial10.1038/s41591-024-03021-7 ↗
14. Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes10.1016/j.cell.2021.03.009 ↗
15. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity10.1002/adma.202002197 ↗
16. NanoRNP overcomes tumor heterogeneity in cancer treatment10.1021/acs.nanolett.9b02501 ↗
17. Multi-omic analysis of gallbladder cancer identifies distinct tumor microenvironments associated with disease progression10.1038/s41588-025-02236-9 ↗
18. Single-cell analysis reveals a longitudinal trajectory of meningioma evolution and heterogeneity10.1038/s41467-025-60653-0 ↗
19. Rational design of metal-organic frameworks for pancreatic cancer therapy: from machine learning screening to in vivo efficacy10.1002/adma.202412757 ↗
20. Rational combinations of targeted cancer therapies: background, advances and challenges10.1038/s41573-022-00615-z ↗
21. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies10.1073/pnas.2322203121 ↗
22. Tumor-on-a-chip model incorporating human-based hydrogels for easy assessment of metastatic tumor inter-heterogeneity10.1002/adfm.202315940 ↗
23. Cell-intrinsic metabolic phenotypes identified in patients with glioblastoma, using mass spectrometry imaging of 13C-labelled glucose metabolism10.1038/s42255-025-01293-y ↗
24. Cancer cell metabolism and antitumour immunity10.1038/s41577-024-01026-4 ↗
25. Smart nanoassembly enabling activatable NIR fluorescence and ROS generation with enhanced tumor penetration for imaging-guided photodynamic therapy
26. vivo aggregation of clearable bimetallic nanoparticles with interlocked surface motifs for cancer therapeutics amplification10.1021/acs.nanolett.3c02399 ↗
27. Metabolites and the tumour microenvironment: from cellular mechanisms to systemic metabolism10.1038/s42255-020-00317-z ↗
28. Metabolites as signalling molecules in the tumour immune microenvironment
29. A multimodal atlas of tumour metabolism reveals the architecture of gene–metabolite covariation10.1038/s42255-023-00817-8 ↗
30. Atomic structure and in situ visualization of native PMEL lamellae in melanosomes10.1038/s41467-025-65221-0 ↗
31. Melanocyte biology and skin pigmentation10.1038/nature05660 ↗
32. Nutrient-delivery and metabolism reactivation therapy for melanoma10.1038/s41565-024-01690-6 ↗
33. Site-specific fabrication of a melanin-like pigment through spatially confined progressive assembly on an initiator-loaded template10.1038/s41467-023-38622-2 ↗
34. Tyrosinase-Woven Melanin Nets for Melanoma Therapy through Targeted Mitochondrial Tethering and Enhanced Photothermal Treatment10.1002/adma.202411906 ↗
35. Coupling of melanocyte signaling and mechanics by caveolae is required for human skin pigmentation10.1038/s41467-020-16738-z ↗
36. Noncationic polymer-assisted carrier for nucleic acid drug delivery10.1007/s40843-024-3048-0 ↗
37. Hydrophobization of Ribonucleic Acids for Facile Systemic Delivery and Multifaceted Cancer Immunotherapy10.1021/acs.nanolett.3c04507 ↗
38. Nanomedicine-mediated immunogenic cell death and its combination with immune checkpoint blockade therapy10.1007/s11431-023-2574-0 ↗
39. Photoactivated Self-Assembled Nanomicelles Integrating Mitophagy Inhibition to Enhance Pyroptosis for Cancer Immunotherapy10.1002/adfm.202504384 ↗
40. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin10.1038/nature22393 ↗
41. Radiofrequency-activated pyroptosis of Bi-valent gold nanocluster for cancer immunotherapy10.1021/acsnano.2c09242 ↗
42. Nanoagonist-mediated GSDME-dependent pyroptosis remodels the inflammatory microenvironment for tumor photoimmunotherapy
43. Thermally gated dual-cascade nanozyme for enhanced mild-temperature photothermal therapy
44. A mild hyperthermia hollow carbon nanozyme as pyroptosis inducer for boosted antitumor immunity10.1021/acsnano.3c07601 ↗
45. Creating single atomic coordination for hypoxia-resistant pyroptosis nano-inducer to boost anti-tumor immunotherapy
46. STING agonist-based ER-targeting molecules boost antigen cross-presentation10.1038/s41586-025-08758-w ↗
47. Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel10.1038/s41551-020-0597-7 ↗